- Reports: Novartis exits vaccines and animal health while acquiring oncology business from GSK
- Novartis names new head of sales U.S.
- GSK, Novartis create an $11 billion consumer healthcare business
- Sandoz starts late-stage trial of Humira biosimilar
- Novartis Consumer Health's return to shelf on track, Theraflu relaunching next
PRINCETON, N.J. — Generic drug maker Sandoz has launched a generic version of a drug used to treat high blood pressure and angina.
The company, a subsidiary of Swiss drug maker Novartis, announced the launch of diltiazem hydrochloride extended-release capsules, a generic version of Forest Labs' Tiazac. Sandoz is launching the drug in the 120-mg, 180-mg, 240-mg, 300-mg, 360-mg and 420-mg strengths.
Various versions of the drug had sales of about $174 million in 2012, according to IMS Health.